Beasley, Allen, Crow, Methvin, Portis & Miles, P.C.

European studies link synthetic insulin product Lantus (insulin glargine), manufactured by Sanofi-Aventis, to higher risk of cancer

The U.S. Food & Drug Administration (FDA) recently notified health care professionals and patients that it is aware of four recently published observational studies that looked at the use of Lantus (insulin glargine) and possible risk for cancer in patients with diabetes. Three of the four studies suggest an increased risk for cancer associated with use of Lantus.

The studies, published in the online journal Diabetologia in June, include 301,136 patients treated with insulin in Germany, Sweden and Britain. Findings were significant enough to cause concern, and calls for further testing.

Prescription Lantus is manufactured by French drugmaker Sanofi-Aventis, and is used for adults with type 2 diabetes or adults and children (6 years and older) with type 1 diabetes who require long-acting insulin for the control of high blood sugar. The company also makes the Lantus SoloSTAR, which is a disposable prefilled insulin pen.

Have you been affected by lantus?

If you or your loved one has suffered a serious injury or are concerned as a result of your use of Lantus, we want to hear from you. Please share your experience, ask questions or let us know your thoughts by posting in our comments, or by filling out the contact form.

You may also call our toll-free number (1-800-808-2034) for a free, no-cost, no-obligation legal evaluation of your case.